| Recruiting | Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevi Chronic Hepatitis D | Phase 2 / Phase 3 | 2026-02-26 |
| Recruiting | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZU Chronic Hepatitis D Infection | Phase 3 | 2026-01-14 |
| Recruiting | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) Fragile X Syndrome | Phase 2 | 2025-11-22 |
| Recruiting | Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Alagille Syndrome | Phase 4 | 2025-09-25 |
| Recruiting | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection Chronic Hepatitis D Infection | Phase 3 | 2025-08-27 |
| Active Not Recruiting | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection Chronic Hepatitis D Infection | Phase 2 / Phase 3 | 2025-03-25 |
| Active Not Recruiting | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Phase 3 | 2024-10-14 |
| Recruiting | Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | — | 2023-09-21 |
| Recruiting | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Ca Primary Biliary Cholangitis, PBC | Phase 2 | 2021-09-22 |
| Completed | A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver D Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease | Phase 2 | 2021-09-09 |
| Completed | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai Biliary Atresia | Phase 2 | 2021-07-08 |
| Terminated | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepati Intrahepatic Cholestasis of Pregnancy | Phase 2 | 2021-01-04 |
| Active Not Recruiting | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Ca Primary Sclerosing Cholangitis | Phase 2 | 2020-12-18 |
| Completed | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) CTX | Phase 3 | 2020-01-31 |
| Completed | MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Cholestatic Liver Disease | Phase 2 | 2020-01-16 |
| Completed | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | 2020-01-08 |
| Completed | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | 2019-07-09 |
| Withdrawn | A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepati Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | 2018-10-25 |
| Active Not Recruiting | The REPLACE Registry for Cholbam® (Cholic Acid) Bile Acid Synthesis Disorders | — | 2017-07-10 |
| Terminated | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Non-Alcoholic Steatohepatitis | Phase 2 | 2016-10-24 |
| Completed | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose Non-Alcoholic Steatohepatitis | Phase 1 | 2015-10-01 |
| Completed | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Healthy Volunteers | Phase 1 | 2015-06-01 |
| Withdrawn | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Bilia Primary Biliary Cirrhosis | Phase 2 | 2015-05-01 |
| Completed | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cho Alagille Syndrome | Phase 2 | 2015-03-16 |
| Completed | Safety and Tolerability Study of SHP626 in Overweight and Obese Adults Non-Alcoholic Steatohepatitis | Phase 1 | 2015-01-19 |
| Completed | Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Alagille Syndrome | Phase 2 | 2014-11-24 |
| Completed | Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Alagille Syndrome | Phase 2 | 2014-10-28 |
| Completed | Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | — | 2014-07-01 |
| Completed | Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholest Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 2 | 2014-03-01 |
| Completed | Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) | Phase 2 | 2014-03-01 |
| Completed | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cho Alagille Syndrome | Phase 2 | 2013-12-20 |
| Completed | Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Sy Alagille Syndrome | Phase 2 | 2013-08-01 |
| Completed | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cir PBC, Primary Biliary Cirrhosis | Phase 2 | 2013-08-01 |
| Completed | Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid S Inborn Errors of Bile Acid Synthesis | Phase 3 | 2010-04-01 |
| Completed | Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis Bile Acid Synthesis Defect | Phase 3 | 2010-01-01 |
| Completed | Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy | Phase 3 | 1992-01-01 |
| Approved For Marketing | A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome Alagille Syndrome | — | — |